Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Trulicity ® (dulaglutid) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Dulaglutide is a GLP-1 RA indicated for once weekly dosing as an adjunct to diet and exercise for the treatment of adults with unsufficiently controlled T2DM.1
No studies have been performed regarding switching to dulaglutide from another GLP-1 RA.
Physicians should follow their clinical judgment, taking into account the patient’s glycemic control, when deciding how to switch from one GLP-1 RA to another one.
When switching a patient from another GLP-1 RA to dulaglutide, the prescribing information of the applicable GLP-1 RA and pharmacokinetic profile should be considered including
onset of action
duration of action
half-life
time to steady state, and
missing dosing information.
Improvement in glycemic control with dulaglutide after the first administration is sustained throughout the once weekly dosing interval. The half-life of dulaglutide is approximately 5 days and steady-state concentrations of dulaglutide are achieved within 2 to 4 weeks.1
1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
GLP-1 RA = glucagon-like peptide-1 receptor agonist
T2DM = type 2 diabetes mellitus
Datum fӧr senaste ӧversyn 2018 M10 11